CSBR: Champions Oncology Inc Bozor kapitallashuvining daromadga nisbati

Champions Oncology Corp (CSBR) kompaniyasining korporativ logotipi

Champions Oncology o'simta modellashtiruvi orqali yuqori texnologiyali shaxsiylashtirilgan saratonni davolash muhitini ishlab chiqmoqda. Savdo daromadlariga nisbatdagi narx ko'rsatkichi biznes qiymati dinamikasini aks ettiradi, bunda joriy parametr 1.10 ni tashkil etadi. Barqarorlik yetakchi diagnostik a’zolarni jalb qilish orqali ta'minlanadi, B2B xizmatlarining kengayishi davridagi mo'tadil operatsion richag esa biobankni saqlash xarajatlarini samarali optimallashtiradi.

Narxning daromadga nisbati: Champions Oncology Inc (CSBR) 04.07.2022 - 16.11.2026 uchun

Champions Oncology Corp (CSBR) kompaniyasining tahliliy kesimlari

- bozor kapitallashuvi haqida ma'lumot:
Kompaniyaning fundamental tahlili:CSBR - Champions Oncology
Champions Oncology Inc yetakchi tovari

Bozor Champions Oncology (CSBR) salohiyatini uning intellektual aktivlarining fundamental qiymati prizmasi orqali baholaydi. P/S koeffitsiyenti bozor kapitalizatsiyasini yillik savdo hajmi bilan solishtirib, investor daromadning bir birligi uchun qancha to'layotganini aniqlaydi. Ushbu grafikdagi P/S darajalarini tahlil qilish orqali aktiv haddan tashqari sotib olinganligini baholash mumkin. Onkologiya sohasidagi past geopolitik xavf bunday koeffitsientlarni yanada barqaror qiladi va aksiyani defensiv aktiv sifatida tavsiflaydi.

Champions Oncology raqobatchilari

ONC - Sotuvga nisbatan narx|P/S multiplikatori HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Sotuvga nisbatan narx|ascentage.com - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati CGON (cgoncology.com)|URGN: P/S multiplikatori|Bicara Therapeutics Inc (BCAX) - P/S multiplikatori|Narxning daromadga nisbati personalis.com|Kapitalizatsiyaning daromadga nisbati Erasca Corp (ERAS)|Kapitalizatsiyaning daromadga nisbati DCTH (Delcath)|Narx/daromad koeffitsiyenti Y-mAbs Therapeutics, Inc.|P/S multiplikatori AURA (Aura Biosciences Inc)|Bozor kapitallashuvining daromadga nisbati CADL|ARAY: Kapitalizatsiyaning daromadga nisbati|Narx/daromad koeffitsiyenti sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiya va daromad nisbati CTOR|Narxning daromadga nisbati TuHURA Biosciences Inc.|TARA: Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Fate Therapeutics (FATE)|Narx/daromad koeffitsiyenti Aadi Bioscience|Narxning daromadga nisbati TScan Therapeutics Inc TCRX|XBIT - Kapitalizatsiyaning daromadga nisbati|CVM - Narxning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati OSTX (OS Therapies)|RADX: P/S multiplikatori|Artiva Biotherapeutics Inc. - Bozor kapitallashuvining daromadga nisbati|ANL (Adlai Nortye) - P/S multiplikatori|P/S multiplikatori verupharma.com|Kapitalizatsiyaning daromadga nisbati TPST (tempesttx.com)|Kapitalizatsiyaning daromadga nisbati Xilio Therapeutics Inc XLO|P/S multiplikatori RENB (Enochian BioSciences)|Mural Bio - Narxning daromadga nisbati|KAPA - Narxning daromadga nisbati|OnKure Therapeutics (OKUR) - Kapitalizatsiyaning daromadga nisbati|GDTC: P/S multiplikatori|Sotuvga nisbatan narx Curis Corp (CRIS)|APLM (apollomicsinc.com) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati Tharimmune Corp (THAR)|P/S multiplikatori ADVB|GNPX - Sotuvga nisbatan narx|Narxning daromadga nisbati calidibio.com CLDI|SBFM - Kapitalizatsiyaning daromadga nisbati|XBIO - Narxning daromadga nisbati|SLRX: Narxning daromadga nisbati|Purple Biotech (PPBT) - Narxning daromadga nisbati|AON - Bozor kapitallashuvining daromadga nisbati|Kapitalizatsiyaning daromadga nisbati BGNE|P/S multiplikatori Checkpoint Therapeutics Inc.|P/S multiplikatori ELEV|Kapitalizatsiyaning daromadga nisbati iCAD ICAD|P/S multiplikatori IKNA (Ikena Oncology, Inc.)|Bozor kapitallashuvining daromadga nisbati NTBL|Viracta Therapeutics, Inc. - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning daromadga nisbati Ascentage Pharma Group Ltd